Novartis

Novartis

Web: Novartis external link
Location: Basel
Discipline: Medicine/Pharmacology
Related to:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
#display_name

Business Jul 19
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects - Q2 net sales were flat (0% cc ) as Growth Products offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosen
Medicine Jul 14

Presbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.   Dailies Total1 Multifocal lenses provide a seamless visual experience offering an alternative to bifocals or reading glasses.

Medicine Jul 7

The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the confirm

Medicine Jun 29
Medicine

Novartis today released new results from the largest global survey to date of people with psoriasis. Findings reveal 84% of people with moderate-to-severe psoriasis suffer discrimination and humiliation, with many being stared at in public (40%) as a resultof their medical condition 1 .

Medicine Jul 13

Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product                                                             

Medicine Jun 30

In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage   Advanced SM is rare and has a poor prognosis

Medicine Jun 28

Agreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline -   Collaboration will co-develop Xenc



website preview

Link

Medicine and Life Sciences